head and neck cancer
HPV Tumor DNA Liquid Biopsy Test Shows Promise for Oropharyngeal Cancer Diagnosis, Surveillance
Researchers studied the accuracy of a commercial HPV tumor DNA blood test in almost 400 patients with HPV-related oropharyngeal squamous cell carcinoma.
Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Premium
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.
Naveris, Mayo Clinic Begin Trial of Circulating Tumor DNA Test in Head and Neck Cancer
Researchers hope to establish the ability of Naveris' NavDx test to guide treatment intensity for patients with HPV-driven head and neck cancer.
With $8 million in seed funding, Droplet is developing a test for minimal residual disease detection in head and neck cancer, with research ongoing for other promising targets.
Naveris Nabs $33.4M Series A Round Expansion to Further Commercialize Virus-Related Cancer Tests
The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.